MicroPort NeuroScientific

MicroPort NeuroScientific FCF Margin

The Free Cash Flow Margin of MicroPort NeuroScientific (2172.HK) as of Oct 27, 2026 is 20.05 %. In the previous year, Free Cash Flow Margin was 36.17 % — a change of -44.58% (lower).

FCF Margin

20.05 %

YoY

-44.58%

Last updated:

Free Cash Flow Margin of MicroPort NeuroScientific is 2025 20.05 % . Free Cash Flow Margin of MicroPort NeuroScientific was 2024 36.17 % . It decreases by -44.58% lower compared to the previous year.

The MicroPort NeuroScientific FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2019
3.58 CNY
Jan 1, 2020
5.90 CNY
Jan 1, 2021
25.97 CNY
Jan 1, 2022
37.77 CNY
Jan 1, 2023
-8.62 CNY
Jan 1, 2024
36.17 CNY
Jan 1, 2025
20.05 CNY
The MicroPort NeuroScientific FCF Margin history
YEARFCF MarginYoY
20.05 %-44.58%
36.17 %-519.48%
-8.62 %-122.83%
37.77 %+45.41%
25.97 %+340.34%
5.90 %+64.72%
3.58 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MicroPort NeuroScientific Stock analysis

What does MicroPort NeuroScientific do? MicroPort NeuroTech Ltd. generates revenue through the research, development, manufacturing, and sales of neuro-interventional medical devices. Its main products include embolization coils, flow-diverting stents, and stent grafts, targeting three key areas of neurovascular diseases: hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke. The company serves domestic and overseas markets, with its products primarily used by hospitals and healthcare providers for treating brain diseases. The firm's focus on neurovascular disease solutions drives its commercial strategy. The company operates under the brand MicroPort NeuroTech Ltd., which is part of the broader MicroPort group. It targets healthcare institutions globally, particularly those specializing in neurovascular care. The firm's product portfolio addresses critical treatment needs in neurovascular conditions, aligning with the growing demand for advanced medical devices in stroke management. Revenue streams are derived from direct sales of its medical devices to hospitals and clinics. MicroPort NeuroTech Ltd. focuses on the domestic and overseas markets, with its products designed for specific neurovascular applications. The company's revenue model relies on the sale of embolization coils, flow-diverting stents, and stent grafts to healthcare providers. These products are essential for treating conditions like hemorrhagic stroke and acute ischemic stroke, which are major causes of neurological disability. The firm's strategy emphasizes innovation in neuro-interventional solutions to capture market share in both local and international segments. MicroPort NeuroScientific is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MicroPort NeuroScientific stock

Free Cash Flow Margin of MicroPort NeuroScientific is 20.05 % in 2025.

Free Cash Flow Margin of MicroPort NeuroScientific changed from 36.17 % to 20.05 %, representing a -44.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin MicroPort NeuroScientific since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's MicroPort NeuroScientific with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — MicroPort NeuroScientific

All Key Metrics — MicroPort NeuroScientific